https://www.selleckchem.com/pr....oducts/epz015666.htm
The combined effects of MTX plus HDACIs were evaluated using a cell viability assay, mass spectroscopy imaging, and subcutaneous and intracranial xenograft models. HDACIs upregulated the ratio of FPGS/GGH expression resulting in increased polyglutamylation of MTX, but also downregulated expression of the target molecule of MTX DHFR. The combination of MTX and vorinostat decreased cell viability in vitro ( .05) and tumor volumes in a subcutaneous model ( .0001), and prolonged survival in an intracranial model ( .01), rel
Like
Comment
Share
